Skip to content

Anavex completes mid-stage study of lead drug in rare brain development disorder

September 10, 2020

Anavex Life Sciences (NASDAQ:AVXL) has completed a Phase 2 clinical trial evaluating Anavex 2-73 (blarcamesine) in patients with Rett syndrome, a rare inherited neurological disorder that occurs primarily in girls that leads to severe impairments. The company plans to release topline results next quarter.

Orally available blarcamesine is a sigma-1 receptor (S1R) agonist. S1Rs play a key role in the modulation of neurotransmission. It is also being investigated for the potential treatment of Parkinson’s disease dementia and mild-to-moderate Alzheimer’s disease.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: